Cloudbreak Pharma to Present at the Stifel 2026 Virtual Ophthalmology Forum

Company to showcase its Multi Kinase Inhibitor (MKI) platform and late-stage clinical programs in pterygium and pinguecula

IRVINE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Cloudbreak Pharma Inc., (HKEX 2592), a clinical stage ophthalmic drug company leveraging its proprietary Multi Kinase Inhibitor (MKI) discovery platform to develop first-in-class and best-in-class therapeutics, today announced that the company will participate in the Stifel 2026 Virtual Ophthalmology Forum, taking place on May 26, 2026.

Cloudbreak will participate in a virtual fireside chat at 4:00pm ET and host virtual one-on-one meetings with institutional investors throughout the day. The company plans to discuss its proprietary Multi Kinase Inhibitor platform and clinical development progress for its lead assets: CBT-001, currently being evaluated in a Phase 3 study as a potential treatment for pterygium, a condition affecting approximately 15 million people in the U.S. alone, and CBT-004, currently entering Phase 3 as a potential treatment for pinguecula, a condition affecting approximately half of all people over age 70, or 50 million people in the U.S. alone.

“We are pleased to have the opportunity to showcase Cloudbreak's Multi Kinase Inhibitor platform and our clinical pipeline to the investment community at the Stifel Virtual Ophthalmology Forum,” said Dr. Jinsong Ni, Chief Executive Officer of Cloudbreak Pharma. “Our MKI platform represents a differentiated approach to treating serious front-of-the-eye diseases where no disease-modifying FDA-approved therapies currently exist. We have two eye drop drugs that, if approved, would be the first-and-only FDA-approved therapies to address these large market diseases. This forum provides an excellent venue to raise awareness of Cloudbreak, raise shareholder awareness and discuss how our science-driven approach to inhibiting multiple disease pathways can transform treatment options for patients.”

The MKI platform uniquely positions Cloudbreak to address significant unmet medical needs in both front-of-eye and back-of-eye ophthalmic diseases. By simultaneously inhibiting multiple receptor tyrosine kinases including PDGF, VEGF, FGF, and PIGF signaling pathways, the MKI approach targets the root cause of these fibrogenic and angiogenic diseases rather than merely treating symptoms.

For more information about the Stifel 2026 Virtual Ophthalmology Forum or to request a meeting with Cloudbreak management, please contact your Stifel representative.

About Pterygium
Pterygium (teh-RIJ-ee-uhm) is a triangular fibrovascular growth on the cornea, connected to the conjunctiva. It is commonly caused by excessive UV exposure and can lead to redness, irritation, foreign body sensation, and, with continued progression, potentially serious vision problems. The company estimates that pterygium impacts as many as 15 million people in the U.S. alone. Of those, approximately 7.5 million are seen annually by an eye doctor, and 3.7 million are formally diagnosed each year by an ophthalmologist or medical optometrist.

There are currently no FDA-approved disease-modifying treatments for pterygium. Most patients are treated for their symptoms using artificial tears, prescription dry eye products and/or off-label NSAIDs or corticosteroids, with significant limitations for long-term use. For more severe cases, approximately +100,000 patients annually elect to have surgery, at a cost of $11,500 per procedure, and recurrence rates are estimated to be as high as 38%.

About Pinguecula
Pinguecula (pin·gwek·yoo·luh) is a round, yellowish, elevated tissue that develops on the surface of the eye. The condition is very common among people with increased UV light exposure and increasing age. The condition impacts over a billion people worldwide, including 50 million people in the US alone, of which 15 million are seen annually by an eye doctor and 3.9 million are formally diagnosed with pinguecula each year most often by an ophthalmologist or optometrist.

When the tissue becomes vascularized or inflamed, it can produce a number of symptoms including ocular redness, discomfort and pain, foreign body sensation and tearing and itching. Depending on the location and size of the pinguecula, it may also make wearing contact lenses uncomfortable or impossible. There are currently no FDA-approved pharmacological treatments for pinguecula. To treat some symptoms, such as dry eye and foreign body sensation, lubricating eye drops may be used. For pinguecula that are larger or inflamed, non-steroidal anti-inflammatory drugs or corticosteroids are used, although the former can be associated with corneal complications, while the latter is associated with glaucoma and cataract formation.

About CBT-001
CBT-001 is a novel, multi-kinase inhibitor (MKI) eye drop being developed for the treatment of pterygium, a common ocular surface disease with no FDA-approved drug therapies. Currently in Phase 3 clinical trials across multiple regions, CBT-001 is designed to target the underlying fibrogenic and angiogenic drivers of the disease rather than just providing symptomatic relief. In earlier studies, the therapy demonstrated meaningful reductions in lesion growth, vascularity, and ocular redness, with a favorable safety profile. If approved, CBT-001 has the potential to become the first pharmacologic treatment for pterygium, potentially delaying or eliminating the need for surgery and addressing a significant unmet medical need.

About CBT-004
CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent VEGF receptor inhibitor. CBT-004 also inhibits PDGF receptors, which play key roles in blood vessel maintenance and tissue remodeling. By inhibiting these growth factors, the formulation is specifically designed to modify the disease by addressing the hyperemia and abnormal vascularization associated with the pinguecula lesion. The preservative-free formulation is designed to minimize potential ocular surface toxicity, positioning it for possible chronic use in this condition affecting the delicate ocular surface.

About Cloudbreak
Cloudbreak Pharma is a clinical stage ophthalmic drug company with a proprietary technology, Multi Kinase Inhibitors (MKI), that is de-risked with human clinical results and is uniquely suitable for both front-of-eye and back-of-eye diseases.

Under the MKI platform, Cloudbreak’s lead asset, the eye drop CBT-001, is in mid-Phase 3 in multiple regions for the treatment of pterygium, a disease impacting 15 million people in the US alone. Its second asset, CBT-004, is entering Phase 3 for pinguecula, a disease impacting about half of all people over age 70. CBT-001 and CBT-004 will potentially be the first and only FDA-approved drug therapies for these high-value conditions. The Company has additional technologies with pre-clinical through Phase 2 product candidates.

The Cloudbreak team is comprised of experienced ophthalmologic scientists and business professionals that are uniquely qualified to bring product candidates from pre-clinical to NDA approval.

For more information, visit: https://cloudbreakpharma.com/

For an informative video, please click here.

Forward Looking Statements

This press release contains forward-looking statements regarding the future performance, plans and prospects of Cloudbreak Pharma, Inc. (with effect from 3 July 2025, shares listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “HKEX”)).

These statements may include research and development (R&D) activities, clinical trial progress and outcomes, regulatory submissions, timelines and approvals, manufacturing and supply operations, product launches and partnerships and/or financial outlook and business strategy.

All forward-looking statements are based on management’s current expectations and assumptions only as of the date hereof. Actual results may differ due to various factors, including clinical or regulatory outcomes (e.g., US or other markets), competitive developments and market dynamics, and/or economic or operational uncertainties.

Cloudbreak Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements to reflect subsequent circumstances, except as required by law. The information contained in this presentation may not be complete and may not contain all particulars required to be disclosed by us under the Rules Governing the Listing of Securities on the HKEX and the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Investors or interested parties should review our public filings with the HKEX and our company’s website (cloudbreakpharma.com) for additional information.

Contacts:

For investors:
Eric Ribner, LifeSci Advisors
eric@lifesciadvisors.com

For partnering opportunities:
partners@cloudbreakpharma.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.